Bone drug switch tested to stop dangerous bone loss
NCT ID NCT05091099
Summary
This study looked at whether switching patients from long-term denosumab treatment to other bone-strengthening drugs (alendronate or zoledronate) could prevent rapid bone loss. It involved 44 postmenopausal women and men over 50 who had been on denosumab for at least three years. The goal was to find a safe and effective next step in managing osteoporosis after stopping the initial medication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Taiwan University Hospital, Yunlin branch
Douliu, Yunlin County, 640, Taiwan
Conditions
Explore the condition pages connected to this study.